Anonymization service for clinical trials is in demand due to policies like Policy 0070 and Health Canada publishing requirements, which require pharmaceutical companies to redact clinical documents for market authorization submissions. Regulatory bodies and other organizations are advocating for clinical data sharing, and some companies have committed to sharing complete Clinical Study Reports (CSRs) and Individual patient data (IPD). The International Committee of Medical Journal Editors (ICMJE) also requires data-sharing statements for clinical trials before publishing in relevant journals. Geninvo provides Anonymization as a service for clinical trial data, which enables our clients to address regulatory requirements with ease and efficiency. Our solutions are compliant with 21 CFR 11 and GDPR to support global data sharing and de-identification requirements.